A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients with Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521775-31-00

Acronym

TAS6417-302

Enrollment

126

Registered

2025-10-06

Start date

2025-11-12

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations

Brief summary

Disease-free survival (DFS) by investigator assessment

Interventions

DRUGCarboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUGPemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion

DRUGZipalertinib

DRUGCisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUGZipalertinib Placebo Tablets is a film-coated tablet that does not contain the active ingredient

DRUGzipalertinib.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Disease-free survival (DFS) by investigator assessment	—

Countries

Belgium, France, Germany, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026